Details of Drug

Details of Drug

 Drug General Information (ID: D1591)
  Drug Name
Tipiracil
  Drug Type Small molecule
  Drug Synonymous
Tipiracil; 183204-74-2; TPI (freebase); UNII-NGO10K751P; MA-1; 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1H-pyrimidine-2,4-dione; NGO10K751P; 5-CHLORO-6-(1-(2-IMINOPYRROLIDINYL) METHYL) URACIL; 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)METHYL]PYRIMIDINE-2,4(1H,3H)-DIONE; TAS-1-462; TPI; 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1h,3h)-pyrimidinedione; Tipiracil [USAN:INN]; 5-CIMU; 5-Chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione; CHEMBL235668; GTPL8696; SCHEMBL1682960; BDBM20079; CHEBI:90879; HY-A0063A; HMS3745A05; BCP24231; BDBM50531739; 5-Chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4-(1H,3H)-dione; ZINC100032379; CS-5895; DB02631; DB09343; NCGC00389632-02; NCGC00389632-07; DB-065427; FT-0758894; A927069; Q21098889; Q27458871; 2,4(1H,3H)-Pyrimidinedione, 5-chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-; 5-Chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione,; 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1,2,3,4-tetrahydropyrimidine-2,4-dione; 5-Chloro-6-{[(2E)-2-imino-1-pyrrolidinyl]methyl}-2,4(1H,3H)-pyrimidinedione; 5-chloro-6-{[(2Z)-2-iminopyrrolidin-1-yl]methyl}pyrimidine-2,4(1H,3H)-dione
    Click to Show/Hide
  Therapeutic Class Antineoplastics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C9H11ClN4O2
  InChI InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)
  InChIKey QQHMKNYGKVVGCZ-UHFFFAOYSA-N
  Canonical SMILES C1CC(=N)N(C1)CC2=C(C(=O)NC(=O)N2)Cl
  External Link
Pubchem ID 6323266

Drug-Drug Interaction Network
  Sunburst Graph
AM002  Affected cellular transport
BM010  Transporter inhibition
  Relation Graph
 Full list of drugs interacting with Tipiracil
      Affected cellular transport
   Transporter inhibition Drug Num:  7
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0393
 
Crizotinib
 
C21H22Cl2FN5O
 
11626560 
Moderate    Inter Info   
[1], [2], [3]
D0515
 
Dolutegravir
 
C20H19F2N3O5
 
54726191 
Moderate    Inter Info   
[4], [5]
D0204
 
Brigatinib
 
C29H39ClN7O2P
 
68165256 
Moderate    Inter Info   
[2], [6], [4]
D0251
 
Capmatinib
 
C23H17FN6O
 
25145656 
Moderate    Inter Info   
[4], [7]
D0569
 
Encorafenib
 
C22H27ClFN7O4S
 
50922675 
Moderate    Inter Info   
[2], [8]
D0590
 
Erdafitinib
 
C25H30N6O2
 
67462786 
Moderate    Inter Info   
[2], [9], [10]
D1411
 
Risdiplam
 
C22H23N7O
 
118513932 
Moderate    Inter Info   
[11], [4]
References
1 Cerner Multum, Inc. "Australian Product Information.".
2 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
4 Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
5 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
6 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
7 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
8 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
9 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
10 Product Information. Tenex (guanfacine). Wyeth-Ayerst Laboratories, Philadelphia, PA.
11 Product Information. Evrysdi (risdiplam). Genentech, South San Francisco, CA.